Macleods – Recall of losartan/hydrochlorothiazide

- On February 21, 2019, Macleods announced a voluntary, consumer-level recall of one lot of losartan/hydrochlorothiazide (HCTZ) tablets due to the detection of trace amounts of an unexpected impurity, identified as N-nitrosodiethylamine (NDEA).

- NDEA is a substance that occurs naturally in certain foods, drinking water, air pollution, and industrial processes, and has been classified as a probable human carcinogen as per International Agency for Research on Cancer classification.

    — Refer to the FDA site for updates regarding angiotensin II receptor blocker recalls.

- The recalled lot was distributed from November 6, 2017 through March 30, 2018:

Product Description	NDC#	Lot#
Losartan potassium and HCTZ 100 mg/25 mg tablets	33342-0052-10	BLM715A

- Losartan/HCTZ tablets are used for the treatment of hypertension (HTN) and to reduce the risk of stroke in patients with HTN and left ventricular hypertrophy.

- Patients should contact their pharmacist or physician who can advise them about an alternative treatment prior to returning their medication. Patients who are on losartan/HCTZ should continue taking their medication, as the risk of harm to a patient's health may be higher if the treatment is stopped immediately without any alternative treatment.

- Patients should contact their healthcare provider if they have experienced any problems that may be related to using the recalled losartan/HCTZ.

- Anyone with an existing inventory of the recalled product should stop use and distribution, and quarantine the product immediately.

- For more information regarding this recall, contact Qualanex (appointed company for Macleods) at **1-888-280-2042**.